Cost effectiveness of option B plus for prevention of mother-to-child transmission of HIV in resource-limited countries: evidence from Kumasi, Ghana

Table 4 Baseline results of primary outcomes

Treatment strategy	Lifetime cost (GHS)*	Lifetime cost (USD)*	Life-years*	QALYs*^Ϯ	ICER (USD)^Ϯ
*Option B*	12,071	6,254	186.4	172.1
Mother	2,617	1,356	16.0	13.1
Children	9,453	4,898	178.5	159.0
Per Child	3,781	1,959	71.4	63.6
*Option B+*	24,364	12,624	196.7	180.2	785
Mother	18,821	9,752	16.1	13.2
Children	5,544	2,872	178.4	167.0
Per Child	2,217	1,149	71.4	66.8

*All costs, life-years, and QALYs are discounted by 3% annual rate.
^ϮQALY = Quality-Adjusted Life-Year; ICER = Incremental Cost-Effectiveness Ratio.
All QALYs are calculated using an adjustment of 0.82 utility per year when living with HIV and an annual discount rate of 0.03.
The ICER value is calculated as follows: \( ICER=\frac{Cos{t}_{OptionB+}-Cos{t}_{OptionB}}{QALY{s}_{OptionB+}- QALY{s}_{OptionB}}. \)

ISSN: 1471-2334